Venetoclax and hypomethylating agent therapy for accelerated and blast phase BCR::ABL negative myeloproliferative and extramedullary disease. Yeoh ZH, Wei A. Leuk Lymphoma 2023;64:757-760.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yeoh ZH, Wei A. Venetoclax and hypomethylating agent therapy for accelerated and blast phase BCR::ABL negative myeloproliferative and extramedullary disease. Leuk Lymphoma 2023;64:757-760.
PMID: 37037568